Jodi A. Muscal, MD

Pfizer Inc
New York, New York, United States

Disclosure information not submitted.

Presentation(s):

• Paper 70 - PHASE 2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE®) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY EWING SARCOMA

  Saturday, November 16, 2024
  8:00 AM – 9:00 AM PST